- > Media & Investors
- > Media Relations
- > Press Releases
- > Daiichi Sankyo to Collaborate on Commercialization of Generic Transdermal Fentanyl Citrate Patches for Long-Acting Cancer Pain Relief
For Immediate Release
Company name: DAIICHI SANKYO COMPANY, LIMITED
Representative: Sunao Manabe, Representative Director, President and COO
(Code no.: 4568, First Section, Tokyo Stock Exchange)
Please address inquiries to Noriaki Ishida, Executive Officer,
Vice President, Corporate Communications Department
Daiichi Sankyo to Collaborate on Commercialization of Generic Transdermal Fentanyl Citrate Patches for Long-Acting Cancer Pain Relief
Tokyo, Japan (August 7, 2017) – Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced a collaboration with Kyukyu Pharmaceutical Co., Ltd. (hereafter, Kyukyu Pharmaceutical) to commercialize generic transdermal fentanyl citrate patches for long-acting cancer pain relief.
The fentanyl citrate patches are a once-daily transdermal opioid analgesic for treatment of moderate to severe cancer pain, and are a generic formulation of Fentos® Tape.
Kyukyu Pharmaceutical is currently applying for marketing authorization from the Japanese Ministry of Health, Labour and Welfare. Following the successful obtainment of that authorization, Kyukyu Pharmaceutical will handle manufacturing, and Daiichi Sankyo will handle marketing and promotion activities, for this product.
Daiichi Sankyo expects that the commercialization of generic transdermal fentanyl citrate patches will help to expand our product lineup of opioid analgesics and will offer a novel treatment option to cancer patients and healthcare providers in Japan.
Kyukyu Pharmaceutical Co., Ltd.
1. Address: Chuo-ku, Tokyo
2. Established: 1963
3. Business: Manufacturing and Sales of Ethical Drugs/OTC Drugs
4. Website: http://www.qqp.co.jp/english/index.html
About Daiichi Sankyo Opioid Analgesics
Daiichi Sankyo believes that expanding our product lineup of opioid analgesics helps patients with cancer to improve their quality of life by relieving pain and contributes to the total care for the life of patients with cancer. In June 2017, Daiichi Sankyo launched hydromorphone hydrochloride Narurapid® Tablets (immediate release formulation) and Narusus® Tablets (once-daily extended release formulation), and is applying for approval for an injection with the same active ingredient. Daiichi Sankyo also launched oxycodone extended release "Daiichi Sankyo" tablets for long-acting cancer pain relief in March 2017, and is expected to launch oxycodone "Daiichi Sankyo" tablets for cancer pain treatment on August 28, 2017.